Q-omics provides the consensus-scored MUC13 profile across patient tissues and cancer cell-line models. MUC13 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MUC13 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, MUC13 RNA expression shows 12,824 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, LIHC, and ESCA as cancer lineages where MUC13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC13 survival associations across molecular data types. MUC13 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC13 RNA expression–survival associations across cancer types. High MUC13 expression shows unfavorable associations in MESO, LUAD and LGG, but favorable associations in SCLC, SKCM and STAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MUC13 RNA expression.
This table summarizes MUC13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MUC13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC13 shows lower tumor expression in KIRP, KICH and KIRC and higher tumor expression in LIHC, LUAD and STAD. The LIHC box plot shows higher MUC13 RNA expression in tumor versus normal tissue (log2 FC = +4.098, t-test p < 0.001).
This table shows molecular features associated with MUC13 in patient tissues and cancer cell lines. In patient samples, MUC13 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
